DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Erythropoietin (EPO) Market with Focus on Asia- Industry Analysis & Outlook (2016-2020)" report to their offering.
Erythropoietin is a substance produced by the kidney that leads to the formation of red blood cells in the bone marrow. It is a glycoprotein hormone which regulates erythropoiesis (Red Blood Cell production). For erythrocyte precursors present in the bone marrow, EPO acts as a cytokine. Commonly referred to as hematopoietin or hemopoietin, erythropoietin is also known to have other biological functions, such as involvement in the wound healing cycle and brain's response to neuronal injury.
People suffering from End Stage Renal Disease (ESRD), HIV or undergoing chemotherapy are not able to produce enough EPO on their own and thus, are administered with synthetic or recombinant erythropoietin which has the similar sequence of amino acids. Recombinant erythropoietin is a kind of therapeutic agent devised using DNA technology.
On the bases of their molecular structure, EPO drugs can be divided into five categories: epoetin-alfa, epoetin-beta, epoetin-omega, epoetin-delta and darbepoetin-alfa. Among these epoetin-alfa and darbepoetin-alfa are most commonly prescribed EPO drugs.
The global EPO drugs market is expected to experience negative growth rate, primarily due to expiry of patents of two most common EPO drugs, epoetin-alfa and darbepoetin-alfa, allowing the entry of biosimilars; posing a serious threat to EPO drugs market. However, the Asia-Pacific region is expected to experience boom period majorly due to improving disposable income and better government medical reimbursement policies.
- Amgen Inc.
- Johnson & Johnson
- Roche Holding AG
Teva Pharmaceutical Industries Limited
Key Topics Covered:
2. Global EPO Market
3. Regional Markets
4. Market Dynamics
5. Competitive Landscape
6. Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/8bvm4p/global